What ALBOMED does

ALBOMED GmbH is a German medical device manufacturer headquartered in Schwarzenbruck, Germany, specializing in viscoelastic substances for ophthalmic surgery and orthopaedic viscosupplementation. The company was founded in 1999 as an expansion of the predecessor entity Pe-Ha-Intraocular (founded 1995) and operates additional facilities in Burgthann (administration) and Unna (logistic and production centers built in 2021 and 2024 respectively). Its portfolio is built around bio-fermented sodium hyaluronate and hydroxypropyl methylcellulose formulations, with five core branded products: Pe-Ha-Luron F, Pe-Ha-Visco and Pe-Ha-Guard for ophthalmology (anterior chamber maintenance, corneal protection, and IOL implantation), and KD Intra-Articular Gel and INNORYOS for intra-articular osteoarthritis treatment. INNORYOS, launched in 2022, combines hyaluronic acid with niacinamide in a dual-effect visco-booster supported by a clinical study showing 37.1% WOMAC total score improvement vs 29.2% for the Synvisc comparator at 26 weeks.

ALBOMED operates a B2B medical device sales model, generating revenue through one-time sales of its viscoelastic devices to healthcare professionals and institutions. Distribution combines direct sales to ophthalmic and orthopaedic surgeons with an international distributor channel covering Europe (workforce spans 5 countries), the Middle East (WHX Dubai presence), and APAC (first APACRS exhibition in 2026). Marketing centers on participation in 11 major international congresses annually (ESCRS, EFORT, ESSKA, WOC, DKOU, APACRS, and others) and published clinical evidence rather than digital demand generation. Pricing is not publicly disclosed; minimum order value is EUR 50 net with 30-day payment terms.

The company holds CE certification since 1997, DIN EN ISO 13485 quality management certification, and MDR (Medical Device Regulation) certification for both its ophthalmic product line (2021) and KD orthopaedic product line (2024). Managing Director Sven Reese leads a privately held, founder/closely-held GmbH with no disclosed external investors, parent company, or public funding rounds. Subsidiary, merger, and acquisition activity is absent. Operations are organized around four sites in Germany with workforce of 11-50 employees, and the company is actively expanding into adjacent geographies through congress participation and humanitarian initiatives (including a EUR 2,026 donation to Doctors of the World for Central African Republic medical assistance).

Name

ALBOMED

Legal name

ALBOMED GmbH

Website

https://albomed.de

Company type

Private

Founded year

1999

Operating status

Operating

Headcount range

11–50 employees

Short description

ALBOMED GmbH is a German medical device manufacturer producing MDR-certified viscoelastic substances for ophthalmic surgery and orthopaedic osteoarthritis treatment, selling directly and through international distributors to surgeons and healthcare institutions.

Ownership category

akta.pro rank

Product category

Ophthalmic and Orthopaedic Viscoelastic Medical Devices

NAICS

Ophthalmic Goods Manufacturing (339115), Surgical Appliance and Supplies Manufacturing (339113), Pharmaceutical and Medicine Manufacturing (3254), Surgical and Medical Instrument Manufacturing (339112)

SIC

Ophthalmic Goods (3851), Surgical & Medical Instruments & Apparatus (3841), Pharmaceutical Preparations (2834)

akta.pro primary industry

Ophthalmology Pharmaceuticals (HLAIAAAL)

akta.pro secondary industry

Ophthalmology Specialty Pharmaceuticals (HLAIACAK)

Keywords

• Ophthalmic viscoelastic devices
• Intra-articular viscosupplementation
• Hyaluronic acid medical devices
• Cataract surgery supplies
• Osteoarthritis injection therapy

Headquarters

HQ city

Schwarzenbruck

HQ country

Germany

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Medical Device Sales: ALBOMED generates revenue through the sale of viscoelastic medical devices for ophthalmology (Pe-Ha-Luron® F, Pe-Ha-Visco®, Pe-Ha-Guard®) and orthopaedics (KD Intra-Articular® Gel, INNORYOS®). Products are sold to healthcare professionals and institutions through direct sales and distributor channels.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

ALBOMED GmbH manufactures and distributes modern viscoelastic medical devices based on bio-fermented sodium hyaluronate and hydroxypropyl methylcellulose for ophthalmology (intraocular surgery applications such as cataract and refractive surgery) and orthopaedics (intra-articular viscosupplementation for osteoarthritis). The company develops, produces, and sells its products directly to healthcare professionals, hospitals, and international distributors from facilities in Schwarzenbruck, Burgthann, and Unna, Germany.

Product overview

ALBOMED is a manufacturer of modern viscoelastics serving two core medical specialties: Ophthalmology and Orthopaedics. In Ophthalmology, the portfolio includes Pe-Ha-Luron® F (cohesive/pseudoplastic sodium hyaluronate for maintaining anterior chamber depth), Pe-Ha-Visco® (hydroxypropyl methylcellulose for corneal tissue protection), and Pe-Ha-Guard® (hydroxypropyl methylcellulose for corneal surface protection). In Orthopaedics, ALBOMED offers KD Intra-Articular® Gel (viscoelastic sodium hyaluronate solution for viscosupplementation) and INNORYOS® (the first visco-booster combining hyaluronic acid with niacinamide for enhanced osteoarthritis treatment). All products are MDR-certified and CE marked.

Differentiator

Problem solved

Functional benefit

Brands

• Pe-Ha-Luron® F: High-quality viscoelastic substance based on bio-fermented sodium hyaluronate for intraocular application; space maintainer that preserves depth of anterior chamber and capsular bag
• Pe-Ha-Visco®
• Pe-Ha-Guard®
• KD Intra-Articular® Gel
• INNORYOS®
• Pe-Ha-Glide®
• Pe-Ha-Blue®

Products and services

• Pe-Ha-Luron® F High-quality viscoelastic substance based on bio-fermented sodium hyaluronate for intraocular application. Preserves depth of anterior chamber and capsular bag with cohesive and pseudoplastic behavior providing excellent protection against mechanical forces. For ophthalmic surgeons performing cataract and refractive surgery.
• Pe-Ha-Visco® High-quality viscoelastic substance based on hydroxypropyl methylcellulose for intraocular application. Serves as volume substitute for aqueous humor and protects corneal tissue during intraocular surgery. For ophthalmic surgeons requiring corneal tissue protection during intraocular procedures.
• Pe-Ha-Guard® Superior viscoelastic based on hydroxypropyl methylcellulose to protect the anterior surface of the cornea. Demonstrates stable hydration of corneal epithelium during surgery, resulting in less dry eye post surgery. For ophthalmic surgeons requiring corneal surface protection and hydration.
• KD Intra-Articular® Gel High-quality viscoelastic solution based on bio-fermented sodium hyaluronate for intra-articular use. Shock absorbing and restores viscoelastic properties of healthy joint fluid for treatment of osteoarthritis in orthopaedic synovial joints. For orthopaedic surgeons and rheumatologists treating osteoarthritis in knee, hip, shoulder, ankle, elbow, and hand joints.
• INNORYOS® First visco-booster for osteoarthritis patients with dual effect of hyaluronic acid and niacinamide. Provides antioxidative effect, limits inflammation, and shows best overall functional behavior for dynamic activities. Combines HA with niacinamide via van-der-Waals bonds for cross-stabilization. For orthopaedic surgeons and rheumatologists treating osteoarthritis patients with viscosupplementation therapy.

Quantifiable outcome

• INNORYOS® 2.2% showed 37.1% WOMAC total score improvement vs 29.2% for Synvisc comparator at 26 weeks
• +4 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Scale indicators5 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• Fidia Farmaceutici: Italian specialty pharma company marketing HA-based viscosupplements (Hyalgan, Hymovis) for osteoarthritis. Direct competitor to ALBOMED's orthopaedic viscosupplementation line and to INNORYOS in EU and international markets.
• Anika Therapeutics: US-based specialty company focused on hyaluronic-acid-based viscosupplementation (Monovisc, Orthovisc) for osteoarthritis. Closely comparable to ALBOMED's KD Intra-Articular Gel and INNORYOS in the orthopaedic viscosupplementation business.
• Bioventus: US-based orthobiologics company selling HA viscosupplements (e.g., Durolane) for knee OA. Competes head-to-head with ALBOMED's KD Intra-Articular Gel and INNORYOS in the viscosupplementation market, particularly in EMEA and selected APAC markets.
• Ferring Pharmaceuticals: Swiss specialty pharma marketing Euflexxa (HA) viscosupplementation for knee OA. A direct competitor to ALBOMED's orthopaedic HA products, particularly in EU and international markets where ALBOMED operates via distributors.

Broad incumbents

• Alcon: Global leader in ophthalmic surgical devices and viscoelastics (e.g., cohesive/dispersive OVDs used in cataract surgery). Competes directly with ALBOMED's Pe-Ha-Luron F, Pe-Ha-Visco, and Pe-Ha-Guard in the operating room but covers a far broader portfolio.
• Carl Zeiss Meditec: Broad ophthalmic surgical supplier covering IOLs, viscoelastics, and visualization systems. While primarily known for IOLs and surgical microscopes, ZEISS OVDs overlap with ALBOMED's Pe-Ha-Luron F and Pe-Ha-Visco products in cataract OR use cases.
• Sanofi (Consumer Health / Synvisc): Global pharmaceutical major whose Synvisc (hylan G-F 20) is the named comparator in ALBOMED's INNORYOS clinical study. Represents the dominant incumbent in the viscosupplementation market where KD Intra-Articular Gel and INNORYOS compete.
• Bausch + Lomb: Major ophthalmology medical device and pharmaceutical manufacturer with a cataract surgery viscoelastic range and surgical consumables. Overlaps with ALBOMED on ophthalmic surgical viscoelastics but operates at much larger scale across multiple eye-care categories.
• Johnson & Johnson Vision (AMO): Surgical ophthalmology division of J&J selling IOLs, viscoelastic devices, and cataract surgery instruments. Directly comparable to ALBOMED's ophthalmology division on OVDs and IOL implantation adjuncts (Pe-Ha-Glide/Pe-Ha-Guard).

Emerging players

• TRB Chemedica: Smaller specialty pharma focused on viscosupplementation (e.g., Ostenil/Hyaluronic acid products) and ophthalmic surgical HA products. Comparable to ALBOMED as a niche HA player active across both orthopaedic viscosupplementation and ophthalmic surgery.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@ALBOMED
• LinkedInlinkedin.com/company/albomed
• Facebookfacebook.com/profile.php

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about ALBOMED